Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HDM1005 in Chinese participants with obesity or overweight
NCT07279194Phase 3Recruiting
- Sponsor
- Huadong Medicine
- Start
- Oct 2025
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
A Phase 3 trial of poterepatide in obesity, sponsored by Huadong Medicine. Started Oct 2025; status: recruiting.
02
Drugs
poterepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07279194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279194.